The chairman of Novartis, Daniel Vasella, now has the same title at Alcon, the eye-care company Novartis wants to acquire in full, the WSJ reports . An independent committee of Alcon board members has balked at the offer price for the 23% or so of Alcon that Novartis doesn't already own, the paper says....
FULL ARTICLE AT WSJ.com: Health Blog